This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Smithkline Beecham Corporation. Active years: 1998-1999.
Location History:
- Welwyn Garden, GB (1998)
- Welwyn Garden City, GB (1999)
Company Filing History:
4 out of 2,198 Years Active: 1998-1999
Title: Michael Joseph Browne: Innovator in Biopharmaceuticals
Introduction
Michael Joseph Browne is a notable inventor based in Welwyn Garden City, GB. He has made significant contributions to the field of biopharmaceuticals, particularly in the area of human serine proteases and therapeutic proteins. With a total of 2 patents, his work has implications for medical treatments and drug development.
Latest Patents
Browne's latest patents include groundbreaking innovations. The first patent focuses on a human serine protease, detailing isolated nucleic acids encoding the protease PSP1, along with the protein obtainable from these nucleic acids. It also covers recombinant host cells transformed with the nucleic acids, as well as oligonucleotides and primer pairs specific for PSP1 polymorphisms. The therapeutic uses of this protein and nucleic acid sequences are also disclosed. The second patent involves therapeutic uses of fusion proteins between mutant IL4/IL13 antagonists. This soluble protein exhibits IL4 and/or IL13 antagonist or partial antagonist activity, comprising an IL4 mutant or variant fused to at least one human immunoglobulin constant domain or fragment thereof.
Career Highlights
Browne is currently associated with SmithKline Beecham Corporation, where he continues to advance his research and development efforts. His work has been instrumental in pushing the boundaries of biopharmaceutical innovations.
Collaborations
Throughout his career, Browne has collaborated with esteemed colleagues, including Helen Elizabeth Clinkenbeard and Peter R Young. These collaborations have further enriched his research and contributed to the success of his projects.
Conclusion
Michael Joseph Browne stands out as an influential inventor in the biopharmaceutical sector. His patents and ongoing work reflect his commitment to advancing medical science and improving therapeutic options.